Personalized immunotherapy (AGS-003) when combined with sunitinib for the treatment of metastatic renal cell carcinoma

被引:22
作者
Figlin, Robert A. [1 ,2 ,3 ,4 ]
机构
[1] Cedars Sinai Med Ctr, Hematol Oncol, Los Angeles, CA USA
[2] Cedars Sinai Med Ctr, Med & Biomed Sci, Los Angeles, CA USA
[3] Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA USA
[4] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA USA
关键词
AGS-003; autologous dendritic cell vaccine; immunotherapy; mTOR; overall survival; renal cell carcinoma; sunitinib; targeted therapy; VEGF; INTERFERON-ALPHA; DENDRITIC CELLS; DOUBLE-BLIND; PHASE-I; IMMUNE-RESPONSE; CANCER; TRIAL; INTERLEUKIN-2; TEMSIROLIMUS; BEVACIZUMAB;
D O I
10.1517/14712598.2015.1063610
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Introduction: AGS-003 is a novel autologous dendritic cell vaccine currently in Phase III clinical development in combination with sunitinib for patients with intermediate- and poor-risk clear cell metastatic renal cell carcinoma (ccmRCC). Areas covered: In addition to research published within the past 15 years demonstrating the efficacy of novel targeted therapies, early-phase clinical trial results recently published for AGS-003 in combination with sunitinib are discussed, as well as the ongoing Phase Ill clinical trial Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma. Expert opinion: AGS-003 in combination with sunitinib is a rational step forward for the clinical management of patients with ccmRCC. If the Phase III Advanced Renal Cell Carcinoma trial is positive, this treatment modality will provide a significant survival benefit with minimal toxicity and could change the standard of care for ccmRCC.
引用
收藏
页码:1241 / 1248
页数:8
相关论文
共 63 条
[1]   Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study [J].
Amato, Robert J. ;
Hawkins, Robert E. ;
Kaufman, Howard L. ;
Thompson, John A. ;
Tomczak, Piotr ;
Szczylik, Cezary ;
McDonald, Mike ;
Eastty, Sarah ;
Shingler, William H. ;
de Belin, Jackie ;
Goonewardena, Madusha ;
Naylor, Stuart ;
Harrop, Richard .
CLINICAL CANCER RESEARCH, 2010, 16 (22) :5539-5547
[2]   Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results [J].
Amin, Asim ;
Dudek, Arkadiusz Z. ;
Logan, Theodore F. ;
Lance, Raymond S. ;
Holzbeierlein, Jeffrey M. ;
Knox, Jennifer J. ;
Master, Viraj A. ;
Pal, Sumanta K. ;
Miller, Wilson H., Jr. ;
Karsh, Lawrence I. ;
Tcherepanova, Irina Y. ;
DeBenedette, Mark A. ;
Williams, W. Lee ;
Plessinger, Douglas C. ;
Nicolette, Charles A. ;
Figlin, Robert A. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2015, 3
[3]  
[Anonymous], PROVENGE SIP T PRESC
[4]  
[Anonymous], J CLIN ONCOL S
[5]  
[Anonymous], ASCO 2010 GEN CANC S
[6]  
[Anonymous], GLOBOCAN KIDN EST CA
[7]  
[Anonymous], NEW ENGL J MED
[8]  
[Anonymous], 2015, NCCN clinical practice guidelines in oncology: Prostate cancer
[9]  
[Anonymous], J CLIN ONCOL S
[10]   Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy [J].
Atkins, Michael B. .
MEDICAL ONCOLOGY, 2009, 26 :18-22